Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1988 1
1989 3
1990 3
1991 1
1992 3
1993 4
1994 6
1995 9
1996 7
1997 12
1998 5
1999 2
2000 9
2001 9
2002 12
2003 11
2004 16
2005 15
2006 16
2007 17
2008 18
2009 15
2010 13
2011 24
2012 10
2013 9
2014 15
2015 15
2016 17
2017 12
2018 9
2019 17
2020 19
2021 12
Text availability
Article attribute
Article type
Publication date

Search Results

343 results
Results by year
Filters applied: . Clear all
Page 1
Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'.
Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S; Working Group Molecular Diagnostics and Therapy. Westphalen BC, et al. Among authors: keilholz u. Eur J Cancer. 2020 Aug;135:1-7. doi: 10.1016/j.ejca.2020.04.019. Epub 2020 Jun 7. Eur J Cancer. 2020. PMID: 32521293 Review.
The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions.
Guigay J, Tahara M, Licitra L, Keilholz U, Friesland S, Witzler P, Mesía R. Guigay J, et al. Among authors: keilholz u. Front Oncol. 2019 Aug 21;9:668. doi: 10.3389/fonc.2019.00668. eCollection 2019. Front Oncol. 2019. PMID: 31497530 Free PMC article. Review.
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.
Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Chiarion Sileni V, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Olofsson Bagge R, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. Keilholz U, et al. Ann Oncol. 2020 Nov;31(11):1435-1448. doi: 10.1016/j.annonc.2020.07.004. Epub 2020 Aug 4. Ann Oncol. 2020. PMID: 32763453
p16, HPV, and Cetuximab: What Is the Evidence?
Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, Beier F, Schulten J, Vermorken JB. Bonner JA, et al. Among authors: keilholz u. Oncologist. 2017 Jul;22(7):811-822. doi: 10.1634/theoncologist.2016-0433. Epub 2017 May 18. Oncologist. 2017. PMID: 28526718 Free PMC article. Review.
Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, Treue D, Stenzinger A, Glimm H, Fröhling S, Kindler T, Brandts CH, Schulze-Osthoff K, Weichert W, Tinhofer I, Klauschen F, Keilholz U, Beule D, Rieke DT. Messerschmidt C, et al. Among authors: keilholz u. Int J Cancer. 2020 Oct 15;147(8):2293-2302. doi: 10.1002/ijc.33123. Epub 2020 Jun 18. Int J Cancer. 2020. PMID: 32468570
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H. Chung HC, et al. Among authors: keilholz u. J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1. J Immunother Cancer. 2019. PMID: 30717797 Free PMC article. Clinical Trial.
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. Zandberg DP, et al. Among authors: keilholz u. Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18. Eur J Cancer. 2019. PMID: 30576970 Free article. Clinical Trial.
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II.
Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, Kölbl O, Hautmann MG, Strutz J, Schreiber F, Bockmühl U, Schilling V, Feyer P, de Wit M, Maschmeyer G, Jungehülsing M, Schroeder U, Wollenberg B, Sittel C, Münter M, Lenarz T, Klussmann JP, Guntinas-Lichius O, Rudack C, Eich HT, Foerg T, Preyer S, Westhofen M, Welkoborsky HJ, Esser D, Thurnher D, Remmert S, Sudhoff H, Görner M, Bünzel J, Budach V, Held S, Knödler M, Lordick F, Wiegand S, Vogel K, Boehm A, Flentje M, Keilholz U. Dietz A, et al. Among authors: keilholz u. Ann Oncol. 2018 Oct 1;29(10):2105-2114. doi: 10.1093/annonc/mdy332. Ann Oncol. 2018. PMID: 30412221 Free article. Clinical Trial.
343 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page